72376
document
Chromium Supplementation and the Effects on Metabolic Status in Women with Polycystic Ovary Syndrome : A Randomized , Double-Blind , Placebo-Controlled Trial . BACKGROUND The aim of the present study was to evaluate the beneficial effects of chromium intake on markers of insulin metabolism and lipid profiles in women with polycystic ovary syndrome ( PCOS ) . METHODS In a prospective , randomized , double-blind , placebo-controlled trial , 64 women with PCOS were randomized to receive 200 µg chromium picolinate supplements ( n = 32 ) or placebo ( n = 32 ) for 8 weeks . Fasting blood samples were obtained at baseline and 8 weeks after the intervention to quantify markers of insulin metabolism and lipid concentrations . RESULTS Chromium supplementation in women with PCOS resulted in significant decreases in serum insulin levels ( -3.6 ± 7.4 vs. +3.6 ± 6.2 µIU/ml , p < 0.001 ) , homeostasis model of assessment-insulin resistance ( HOMA-IR ; -0.8 ± 1.6 vs. +0.9 ± 1.5 , p < 0.001 ) , homeostatic model assessment-beta cell function ( HOMA-B ; -15.5 ± 32.3 vs. +13.6 ± 23.1 , p < 0.001 ) , and a significant increase in quantitative insulin sensitivity check index ( QUICKI ) score ( +0.02 ± 0.03 vs. -0.008 ± 0.02 , p = 0.001 ) compared with the placebo . In addition , a trend toward a significant effect of chromium supplementation on decreasing serum triglycerides ( -12.4 ± 74.4 vs. +15.2 ± 32.4 mg/dl , p = 0.05 ) , very low-density lipoprotein-cholesterol ( -2.5 ± 14.9 vs. +3.0 ± 6.5 mg/dl , p = 0.05 ) , and cholesterol concentrations ( -8.6 ± 21.9 vs. +0.7 ± 22.4 mg/dl , p = 0.09 ) was seen . CONCLUSIONS Eight weeks of chromium supplementation among PCOS women had favorable effects on markers of insulin metabolism .
72377
Intervention_Pharmacological
Chromium Supplementation
72378
Intervention_Pharmacological
chromium
72379
Intervention_Control
placebo-controlled
72380
Intervention_Pharmacological
Chromium
72381
Outcome_Physical
Metabolic Status
72382
Outcome_Physical
insulin metabolism
72383
Outcome_Physical
lipid profiles
72384
Participant_Sex
Women
72385
Participant_Condition
Polycystic Ovary Syndrome
72386
Participant_Sex
women
72387
Participant_Condition
polycystic ovary syndrome ( PCOS )
72388
Participant_Sample-size
64
72389
Participant_Sex
women
72390
Participant_Condition
PCOS